株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の嚢胞性繊維症(CF症)治療薬市場の見通し

Global Cystic Fibrosis Therapeutics Market Outlook 2022

発行 RNCOS E-Services Pvt. Ltd. 商品コード 531427
出版日 ページ情報 英文 140 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
世界の嚢胞性繊維症(CF症)治療薬市場の見通し Global Cystic Fibrosis Therapeutics Market Outlook 2022
出版日: 2017年07月12日 ページ情報: 英文 140 Pages
概要

当レポートでは、嚢胞性繊維症(CF)治療薬の世界市場について調査し、疾病および主要製品の概要、薬品クラス・種類・変異タイプ・地域別の詳細動向、市場の推移と予測、市場促進要因・阻害要因ならびに市場機会の分析、パイプラインの分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

第1章 アナリストの見解

第2章 調査手法

第3章 嚢胞性繊維症の概要

第4章 市場力学

  • 促進要因
  • 阻害要因
  • 市場機会

第5章 嚢胞性繊維症治療薬の世界市場

第6章 主要製品

  • Orkambi
  • Kalydeco
  • Cayston
  • Pulmozyme
  • TOBI
  • Creon
  • Zenpep
  • Ventolin
  • Bronchitol
  • ADEKplusTM
  • Ibuprofen

第7章 市場区分:薬品クラス別

  • 嚢胞性線維症膜コンダクタンス制御因子(CFTR)モジュレーター
  • 除痰剤
  • 膵酵素製剤
  • 抗生物質
  • その他

第8章 市場区分:種類別

  • 低分子医薬品
  • バイオ医薬品

第9章 市場区分:変異タイプ別

  • 商品化
    • クラスI
    • クラスII
    • クラスIII
  • 未商品化
    • クラスIV
    • クラスV
    • クラスVI

第10章 市場区分:地域別

  • 北米
  • 欧州
  • アジア太平洋

第11章 産業動向

  • 遺伝子検査
  • 技術進歩
  • CFTRモジュレーター
  • 戦略的提携の増加
  • 併用療法
  • ベンダーによる医療費支援プログラム
  • 研究開発(R&D)の活発化

第12章 パイプラインの分析

  • パイプライン分析:開発段階別
  • パイプライン分析:主要企業別
  • パイプライン分析:地域別
  • パイプライン分析:認証経路別

第13章 ファイブフォース分析

第14章 競合情勢

  • 主要企業の市場シェア

第15章 企業プロファイル

目次

The Global Cystic Fibrosis Therapeutics industry has reported a tremendous growth in the recent years, and is presenting ample opportunities to the industry players. With improving life expectancy and rising awareness, the global cystic fibrosis therapeutics market is poised to scale newer acmes. Also, there lies enormous opportunity for industry participants to tap the fast growing market, which would garner huge revenue on the back of rising strategic consolidations and commercialization of the new drugs targeting the CFTR gene or protein.

The latest research by RNCOS titled, "Global Cystic Fibrosis Therapeutics Market Outlook 2022", unfolds the market dynamics of the cystic fibrosis therapeutics market. According to this new research report, the market for cystic fibrosis therapeutics was valued at US$ 1.94 Billion in 2016.

The report showcases the segmentation of cystic fibrosis therapeutics market on the basis of the pharmacological class, mutation class, drug molecule type, and geographical penetration. It also provides an insight on the current market scenario, as well as forecasts of the aforementioned segments till 2022. The report provides an in-depth analysis of all the major segments, taking into account the major developments taking place at global level in the respective segments that will further boost the growth of cystic fibrosis therapeutics market.

Based on pharmacological class, the report broadly categorizes cystic fibrosis therapeutics market into Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Mucolytic agents, Pancreatic Enzymes products, Antibiotics, and Other therapies. CFTR modulators emerged as the major revenue earners of the industry, holding the largest share. This large share of the market is attributed to recent market approvals of Kalydeco (ivacaftor) and Orkambi (lumacaftor and ivacaftor) for the treatment of patients with CF and robust pipeline.

Based on CF mutation class, the cystic fibrosis therapeutics market is further categorized into commercialized and non-commercialized mutation class specific therapies. CFTR mutation Class II accounted for largest share in the total cystic fibrosis therapeutics market in 2016.

Based on drug molecule type, the cystic fibrosis therapeutics market is further categorized into small molecule and biologic. The small molecule segment accounted for largest share in the total cystic fibrosis therapeutics market in 2016.

Additionally, the report covers the geographic analysis of the global cystic fibrosis therapeutics market by segmenting into three major geographic regions - North America, Europe, and Asia Pacific. North America is the largest market for cystic fibrosis. This high share is attributed to increasing awareness in the market, coupled with growing research initiatives. However, the European market is poised to witness the highest growth owing to increasing focus of players in this region.

Besides, the report covers the profiles of key players like Genentech, Inc. (A Member of the Roche Group), Novartis, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Gilead Sciences, Inc., Allergan plc, etc. with the key financials, providing a comprehensive outlook of global cystic fibrosis therapeutics industry. In addition, the report elucidates key developments of players related to cystic fibrosis industry. Overall, the report provides all the pre-requisite information for clients looking to venture in this industry, and facilitate them to formulate schemes while going for an investment/partnership in the industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Cystic Fibrosis: An Overview

4. Market Dynamics

  • 4.1 Drivers
    • 4.1.1 Robust Pipeline
    • 4.1.2 Rising Prevalence of Cystic Fibrosis
    • 4.1.3 Rising Life expectancy of Cystic Fibrosis Patient's
    • 4.1.4 Improvement in Diagnostic Technologies
    • 4.1.5 Increasing Awareness
    • 4.1.6 Unmet Medical Needs
  • 4.2 Restraints
    • 4.2.1 Cystic Fibrosis Related Complications
    • 4.2.2 Increased Risk of Bacterial Infections in Cystic Fibrosis Patients
    • 4.2.3 High Cost
  • 4.3 Opportunities
    • 4.3.1 Patent Expiry of Biggest-Selling Drugs
    • 4.3.2 Gene Therapy Breakthrough for Cystic Fibrosis

5. Global Cystic Fibrosis Therapeutics Market Outlook 2022

6. Major Marketed Products

  • 6.1 Orkambi (lumacaftor/ivacaftor)
  • 6.2 Kalydeco (Ivacaftor)
  • 6.3 Cayston (Inhaled Aztreonam)
  • 6.4 Pulmozyme (Dornase Alfa)
  • 6.5 TOBI
  • 6.6 Creon
  • 6.7 Zenpep
  • 6.8 Ventolin
  • 6.9 Bronchitol (Inhaled Mannitol)
  • 6.10 ADEKplusTM
  • 6.11 Ibuprofen

7. Market Segmentation by Pharmacological Class

  • 7.1 CFTR modulators
  • 7.2 Mucolytic Agents
  • 7.3 Pancreatic Enzyme Replacement Products
  • 7.4 Antibiotics
  • 7.5 Other Therapies

8. Market Segmentation by Drug Molecule

  • 8.1 Small Molecule
  • 8.2 Biologic Drugs

9. Market Segmentation by Cystic Fibrosis Mutation Type

  • 9.1 Commercialized
    • 9.1.1 Class I
    • 9.1.2 Class II
    • 9.1.3 Class III
  • 9.2 Non-Commercialized
    • 9.2.1 Class IV
    • 9.2.2 Class V
    • 9.2.3 Class VI

10. Market Segmentation by Geography

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia Pacific

11. Industry Trends & Developments

  • 11.1 Genetic Testing
  • 11.2 Technological Advances
  • 11.3 CFTR Modulators - Gaining Momentum
  • 11.4 Upsurge in the Number of Strategic Alliances
  • 11.5 Combination Therapy
  • 11.6 Co-pay and Assistance Programs by Vendors
  • 11.7 Increased R&D Activities: Pillars for Market Growth

12. Cystic Fibrosis Pipeline Analysis

  • 12.1 Pipeline Analysis by Phase of Development
  • 12.2 Pipeline Analysis by Key Players
  • 12.3 Pipeline Analysis by Geography
  • 12.4 Pipeline Analysis by Routes of Administration

13. Porter's Five Forces Analysis

14. Competitive Landscape

  • 14.1 Share of Major Players

15. Company Profiles

  • 15.1 Genentech, Inc. (A Member of the Roche Group)
  • 15.2 Novartis
  • 15.3 Vertex Pharmaceuticals Incorporated
  • 15.4 Abbott Laboratories
  • 15.5 Gilead Sciences, Inc.
  • 15.6 Johnson & Johnson
  • 15.7 Allergan plc
  • 15.8 GlaxoSmithKline
  • 15.9 Mylan N.V.
  • 15.10 Pharmaxis Ltd

List of Figures:

  • Figure 4-1: %age of CF individuals over the age of 18
  • Figure 4-2: Estimated Prevalence of Cystic Fibrosis per 100,000 Habitants, 2015-2016
  • Figure 4-3: Effect of novel therapies on life expectancy of cystic fibrosis patients
  • Figure 5-1: Global - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
  • Figure 6-1: Global - Sales of Orkambi (Million US$), 2015 & 2016
  • Figure 6-2: Global - Sales of Kalydeco (Million US$), 2012-2016
  • Figure 6-3: Global - Sales of Cayston (Million US$), 2014-2016
  • Figure 6-4: Global - Sales of Pulmozyme (Million US$), 2012-2016
  • Figure 6-5: Global - Sales of TOBI (Million US$), 2014-2016
  • Figure 6-6: Global - Sales of Creon (Million US$), 2014-2016
  • Figure 6-7: Global - Sales of Zenpep (Million US$), 2014-2016
  • Figure 6-8: Global - Sales of Ventolin (Million US$), 2014-2016
  • Figure 6-9: Global - Sales of Bronchitol (Million US$), 2014-2016
  • Figure 7-1: Global - Cystic Fibrosis Therapeutics Market Breakup by Pharmacological Class (%), 2016
  • Figure 7-2: Global - CFTR Modulator Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 7-3: Global - Mucolytic Agents Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 7-4: Global - Pancreatic Enzyme Replacement Products Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 7-5: Global - Antibiotics Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 7-6: Global - Other Therapies Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 8-1: Global - Cystic Fibrosis Therapeutics Market by Drug Molecule Type (%), 2016
  • Figure 8-2: Global - Small Molecule Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 8-3: Global - Biologic Drugs Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 9-1: Global - Cystic Fibrosis Therapeutics Market Breakup by CF Mutation Type (%), 2016
  • Figure 9-2: Global - Class I Gene Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 9-3: Prevalence of the F508del Mutation in Patients with Cystic Fibrosis (% of Patients with at Least 1 Allele)
  • Figure 9-4: Global - Class II Gene Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 9-5: Global - Class III Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
  • Figure 10-1: Global - Cystic Fibrosis Therapeutics Market Breakup by Geography (%), 2016
  • Figure 10-2: North America - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
  • Figure 10-3: Europe - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
  • Figure 10-4: Asia-Pacific - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
  • Figure 12-1: Global - Cystic Fibrosis Clinical Trials by Phase till June, 2017
  • Figure 12-2: Global - Cystic Fibrosis Clinical Trials by Key Players till June, 2017
  • Figure 12-3: Global - Cystic Fibrosis Clinical Trials by Countries till June, 2017
  • Figure 12-4: Global - Cystic Fibrosis Clinical Trials by Route of Administration till June, 2017
  • Figure 14-1: Global - Share of Major Players in Cystic Fibrosis Therapeutics Market (%), 2016
  • Figure 15-1: F. Hoffman La Roche Ltd. - Breakup of Revenue by Business Segments (%), 2016
  • Figure 15-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Segments (%), 2016
  • Figure 15-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Geography (%), 2016
  • Figure 15-4: Novartis - Sales by Business Segments (%), 2016
  • Figure 15-5: Novartis - Innovative Medicines Division Sales by Segments (%), 2016
  • Figure 15-6: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016
  • Figure 15-7: Novartis - Sales by Geography (%), 2016
  • Figure 15-8: Vertex Pharmaceuticals Incorporated - Breakup of Revenue by Product (%), 2016
  • Figure 15-9: Vertex Pharmaceuticals Incorporated - Breakup of Revenue by Geography (%), 2016
  • Figure 15-10: Abbott Laboratories - Net Sales Breakup by Business Segments (%), 2016
  • Figure 15-11: Abbott Laboratories - Net Sales Breakup by Geography (%), 2016
  • Figure 15-12: Gilead Sciences, Inc. - Breakup of Revenue by Geographic Segments (%), 2016
  • Figure 15-13: Johnson & Johnson - Sales by Business Segments (%), 2016
  • Figure 15-14: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016
  • Figure 15-15: Johnson & Johnson - Sales by Geography (%), 2016
  • Figure 15-16: Allergan plc - Breakup of Revenue by Business Segments (%), 2016
  • Figure 15-17: Allergan plc - Breakup of Revenue by Geography (%), 2016
  • Figure 15-18: GlaxoSmithKline plc - Breakup of Revenue by Business Segments (%), 2016
  • Figure 15-19: GlaxoSmithKline plc - Pharmaceuticals Division Revenue by Segments (%), 2016
  • Figure 15-20: GlaxoSmithKline plc - Breakup of Revenue by Geography (%), 2016
  • Figure 15-21: Mylan N.V. - Breakup of Revenue by Geographic Region (%), 2016
  • Figure 15-22: Pharmaxis Ltd - Breakup of Revenue by Business Segment (%), 2016

List of Tables:

  • Table 4 -1: Global - Key Cystic Fibrosis Drugs and Patent Expiry Status
  • Table 12-1: Global - Cystic Fibrosis Products Pipeline Analysis
  • Table 14-1: Global - Major Cystic Fibrosis Drugs
  • Table 15-1: F. Hoffman La Roche Ltd. - Key Financials (Billion US$), 2014-2016
  • Table 15-2: Genentech, Inc. - Commercialized Cystic Fibrosis Product
  • Table 15-3: Genentech, Inc. - Cystic Fibrosis Drugs in Pipeline
  • Table 15-4: Novartis - Key Financials (Billion US$), 2014-2016
  • Table 15-5: Novartis - Commercialized Cystic Fibrosis Product
  • Table 15-6: Novartis - Cystic Fibrosis Drugs in Pipeline
  • Table 15-7: Vertex Pharmaceuticals Incorporated - Key Financials (Million US$), 2014-2016
  • Table 15-8: Vertex Pharmaceuticals Incorporated - Commercialized Cystic Fibrosis Product
  • Table 15-9: Vertex Pharmaceuticals Incorporated - Cystic Fibrosis Drugs in Pipeline
  • Table 15-10: Abbott Laboratories - Key Financials (Million US$), 2014-2016
  • Table 15-11: Abbott Laboratories - Commercialized Cystic Fibrosis Product
  • Table 15-12: Gilead Sciences, Inc. - Key Financials (Billion US$), 2014-2016
  • Table 15-13: Gilead Sciences, Inc. - Commercialized Cystic Fibrosis Product
  • Table 15-14: Gilead Sciences, Inc. - Cystic Fibrosis Drugs in Pipeline
  • Table 15-15: Johnson & Johnson - Key Financials (Billion US$), 2014-2016
  • Table 15-16: Johnson & Johnson - Commercialized Cystic Fibrosis Product
  • Table 15-17: Allergan plc - Key Financials (Million US$), 2014-2016
  • Table 15-18: Allergan plc - Commercialized Cystic Fibrosis Product
  • Table 15-19: GlaxoSmithKline plc - Key Financials (Million US$), 2014-2016
  • Table 15-20: GlaxoSmithKline plc - Commercialized Cystic Fibrosis Product
  • Table 15-21: GlaxoSmithKline plc - Cystic Fibrosis Drugs in Pipeline
  • Table 15-22: Mylan N.V. - Key Financials (Million US$), 2014-2016
  • Table 15-23: Mylan N.V. - Commercialized Cystic Fibrosis Product
  • Table 15-24: Pharmaxis Ltd - Key Financials (Million US$), 2014-2016
  • Table 15-25: Pharmaxis Ltd - Commercialized Cystic Fibrosis Product
  • Table 15-26: Pharmaxis Ltd - Cystic Fibrosis Drugs in Pipeline
Back to Top